Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
Micardis(R) - Micardis Plus(R) - Klinische Wirksamkeit (39 Abbildungen)
Übersicht


Zum ersten Bild Abb. 27: Morgendliche Blutdrucksenkung Abb. 28: Klinische Wirksamkeit - MicardisPlus Abb. 29: Telmisartan - HCTZ Aktuelles Bild - Abb. 30: Telmisartan - HCTZ Abb. 31: Telmisartan - HCTZ Abb. 32: Telmisartan - Losartan - HCTZ Abb. 33: Telmisartan - Losartan - HCTZ Zum letzten Bild
Abbildung 30: Telmisartan - HCTZ
Reported here are selected arms from an 8-week, 4 x 5 factorial, multicentre, double-blind, placebo-controlled, dose-finding study conducted in 818 patients with mild-to-moderate hypertension.1 Patients were randomized to telmisartan 20 mg, 40 mg, 80 mg or 160 mg alone or in combination with HCTZ 6.25 mg, 12.5 mg, or 25 mg, giving a total of 20 treatment groups. Combination therapy significantly improved the SBP response rate compared with monotherapy (P<0.01). 1. McGill JB, Reilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001; 23: 833–850.
 
Telmisartan - HCTZ
Vorheriges Bild Nächstes Bild   


Abbildung 30: Telmisartan - HCTZ
Reported here are selected arms from an 8-week, 4 x 5 factorial, multicentre, double-blind, placebo-controlled, dose-finding study conducted in 818 patients with mild-to-moderate hypertension.1 Patients were randomized to telmisartan 20 mg, 40 mg, 80 mg or 160 mg alone or in combination with HCTZ 6.25 mg, 12.5 mg, or 25 mg, giving a total of 20 treatment groups. Combination therapy significantly improved the SBP response rate compared with monotherapy (P<0.01). 1. McGill JB, Reilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001; 23: 833–850.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung